M
Mignon L. Loh
Researcher at University of California, San Francisco
Publications - 472
Citations - 42124
Mignon L. Loh is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Leukemia & Medicine. The author has an hindex of 82, co-authored 407 publications receiving 35918 citations. Previous affiliations of Mignon L. Loh include Children's Oncology Group & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Impact of Vincristine-Steroid Pulses in Maintenance for B-Cell Pediatric ALL: A Systematic Review and Meta-Analysis.
Louise Guolla,Sara Breitbart,Farid Foroutan,Lehana Thabane,Mignon L. Loh,David T. Teachey,Elizabeth A. Raetz,Sumit Gupta +7 more
TL;DR: A systematic review and meta-analysis examined the impact of reducing frequency of vincristine-steroid pulses during maintenance for newly diagnosed pediatric patients with B-cell ALL as mentioned in this paper .
Journal ArticleDOI
Abstract 2002: A genome-wide association study identifies novel sepsis risk loci in children with Down syndrome-associated acute lymphoblastic leukemia: A report from the Children’s Oncology Group
Melissa A. Richard,Meenakshi Devidas,Wenjian Yang,John P. Woodhouse,A. Rodriguez,Johann Hitzler,Reuven J. Schore,Anne L. Angiolillo,Michael J. Burke,Wanda L. Salzer,Elizabeth A. Raetz,Mignon L. Loh,Stephen P. Hunger,Jun Yang,Philip J. Lupo,Karen R. Rabin +15 more
TL;DR: Findings suggest zinc homeostasis may be an important factor mediating risk of sepsis during treatment of individuals with DS-ALL, and a genome-wide association study identifies novelSepsis risk loci in children with Down syndrome-associated acute lymphoblastic leukemia.
and Noonan Syndrome/myeloproliferative disease The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia
Bruce D. Gelb,Marco Tartaglia,Mignon L. Loh,Gabriela Kardos,Cornelia Klein,Seiji Kojima,Jan Stary,M. Trebo,Christian P. Kratz,Charlotte M. Niemeyer,Robert P. Castleberry,Mualla Cetin,Eva Bergsträsser,Peter D +13 more
Journal ArticleDOI
Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931
Luke Maese,Mignon L. Loh,Mi Rim Choi,Tong Lin,Etsuko Aoki,Shirali Agarwal,Xiaotian Wu,Robert Iannone,Jeffrey A. Silverman,Lewis B. Silverman,Elizabeth A. Raetz,Rachel E. Rau +11 more
TL;DR: The AALL1931 trial as discussed by the authors was a two-part, open-label, phase 2/3 trial conducted in collaboration with the Children's Oncology Group investigating efficacy, safety, and pharmacokinetics (PK) of JZP458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).
Journal ArticleDOI
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Kelly Faulk,John A. Kairalla,ZoAnn E. Dreyer,Andrew J. Carroll,Nyla A. Heerema,Meenakshi Devidas,William L. Carroll,Elizabeth A. Raetz,Mignon L. Loh,Stephen P. Hunger,Michael Horowitz,Cindy Wang,Erin M. Guest,Patrick A. Brown +13 more
TL;DR: In this article , the authors measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study.